{"product_id":"coherus-bcg-matrix","title":"Coherus Biosciences Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious about Coherus Biosciences' product portfolio? Our BCG Matrix analysis highlights key areas like their potential \"Stars\" and established \"Cash Cows.\"\u003c\/p\u003e\n\u003cp\u003eThis preview offers a glimpse into how Coherus Biosciences' products are positioned in the market. To truly understand their strategic direction and identify growth opportunities, you need the full picture.\u003c\/p\u003e\n\u003cp\u003ePurchase the complete Coherus Biosciences BCG Matrix for a detailed quadrant-by-quadrant breakdown and actionable insights to inform your investment and product strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLOQTORZI (toripalimab-tpzi)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLOQTORZI, Coherus's flagship oncology product, is positioned as a star in their BCG matrix. It holds the distinction of being the first and only FDA-approved therapy for all patient groups and lines of treatment in recurrent or metastatic nasopharyngeal carcinoma (NPC). This unique market position suggests high growth potential.\u003c\/p\u003e\n\u003cp\u003eThe financial performance of LOQTORZI is robust, with net revenue climbing 29% from the third quarter to the fourth quarter of 2024. Furthermore, patient demand saw a significant uptick of over 15% in the first quarter of 2025 compared to the preceding quarter, underscoring its growing market traction.\u003c\/p\u003e\n\u003cp\u003eCoherus is strategically focused on amplifying LOQTORZI's revenue streams. This involves broadening its application within NPC and exploring new therapeutic areas through combinations with its existing pipeline and external partnerships, solidifying its star status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCHS-114 (anti-CCR8 antibody)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCHS-114, an anti-CCR8 antibody from Coherus Biosciences, is currently in Phase 1 trials for advanced solid tumors, including head and neck squamous cell carcinoma (HNSCC). This selective antibody targets and depletes CCR8+ regulatory T cells, demonstrating a favorable safety profile in early studies. \u003c\/p\u003e\n\u003cp\u003ePositive Phase 1b data for CHS-114 in head and neck cancer were presented at the 2025 AACR Annual Meeting, highlighting its potential. Coherus is actively pursuing combination studies with LOQTORZI in second-line HNSCC and gastric cancer, with anticipated data readouts in Q2 2026. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCasdozokitug (IL-27 antagonist antibody)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCasdozokitug, an IL-27 antagonist antibody, is positioned as a potential Star in Coherus Biosciences' BCG Matrix. Its first-in-class status and ongoing evaluation in Phase 1\/2 studies for advanced solid tumors, alongside a Phase 2 study in hepatocellular carcinoma (HCC), highlight its significant growth potential. \u003c\/p\u003e\n\u003cp\u003eThe company is actively enrolling patients in a Phase 2 randomized trial combining casdozokitug with toripalimab and bevacizumab for first-line HCC treatment. Initial data from this crucial trial is anticipated in the first half of 2026, which could further solidify its Star status if positive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture LOQTORZI Combinations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCoherus Biosciences is strategically expanding LOQTORZI's utility by exploring combinations with both its own pipeline candidates and external therapies. This approach is designed to overcome immune resistance and create synergistic benefits, positioning LOQTORZI as a foundational element in future cancer treatment regimens.\u003c\/p\u003e\n\u003cp\u003eThe company is actively investigating LOQTORZI's potential when paired with promising oncology agents during 2025. This initiative is geared towards achieving significant sales multiples and realizing synergistic growth opportunities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eLOQTORZI Combination Pipeline:\u003c\/strong\u003e Coherus is developing novel combinations for LOQTORZI, targeting immune resistance and synergistic effects.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2025 Evaluation Focus:\u003c\/strong\u003e The company plans to evaluate LOQTORZI with promising cancer agents in 2025 to drive sales multiples and synergies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Partnerships:\u003c\/strong\u003e Coherus is pursuing external partnerships to broaden LOQTORZI's combination therapy options.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Pipeline Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCoherus Biosciences is strategically expanding into oncology with a focus on innovative immuno-oncology candidates. These aim to boost the body's immune response against cancer, potentially leading to better patient outcomes.\u003c\/p\u003e\n\u003cp\u003eThe company anticipates significant progress with multiple clinical data readouts from its oncology pipeline expected in 2025 and 2026. This aggressive development schedule underscores Coherus's dedication to introducing novel, high-growth products in the expanding oncology market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Focus:\u003c\/strong\u003e Innovative immuno-oncology candidates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Goal:\u003c\/strong\u003e Enhance immune responses and improve cancer patient outcomes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKey Milestones:\u003c\/strong\u003e Multiple clinical data readouts anticipated in 2025-2026.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Position:\u003c\/strong\u003e Targeting growth in the expanding oncology sector.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCoherus's Oncology Stars: LOQTORZI \u0026amp; Casdozokitug\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLOQTORZI, Coherus's leading oncology product, is firmly established as a Star in their BCG matrix. Its position as the sole FDA-approved therapy for all patient groups and treatment lines in recurrent or metastatic nasopharyngeal carcinoma (NPC) signifies substantial market potential and high growth. The company is actively working to maximize LOQTORZI's revenue by expanding its use in NPC and exploring new therapeutic avenues through strategic combinations.\u003c\/p\u003e\n\u003cp\u003eCasdozokitug, an IL-27 antagonist antibody, is also identified as a potential Star. Its first-in-class status and ongoing Phase 1\/2 trials for advanced solid tumors, including a Phase 2 study in hepatocellular carcinoma (HCC), underscore its significant growth prospects. Coherus is actively pursuing a Phase 2 randomized trial combining casdozokitug with established therapies for first-line HCC, with initial data expected in the first half of 2026.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eBCG Matrix Position\u003c\/th\u003e\n\u003cth\u003eKey Growth Drivers\u003c\/th\u003e\n\u003cth\u003e2024\/2025 Data Points\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLOQTORZI\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003ctd\u003eFirst and only FDA-approved for all NPC lines; expanding combinations\u003c\/td\u003e\n\u003ctd\u003eNet revenue up 29% Q3-Q4 2024; Patient demand up \u0026gt;15% Q1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCasdozokitug\u003c\/td\u003e\n\u003ctd\u003ePotential Star\u003c\/td\u003e\n\u003ctd\u003eFirst-in-class IL-27 antagonist; ongoing Phase 1\/2 \u0026amp; 2 trials\u003c\/td\u003e\n\u003ctd\u003eData from first-line HCC combination trial anticipated H1 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis BCG Matrix analysis provides a tailored overview of Coherus Biosciences' product portfolio, identifying strategic opportunities and challenges within each quadrant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCoherus Biosciences' BCG Matrix offers a clear, visual pain point reliever by simplifying complex portfolio analysis.\u003c\/p\u003e\n\u003cp\u003eThis tool provides a strategic roadmap, alleviating the pain of resource allocation decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUDENYCA (pegfilgrastim-cbqv)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUDENYCA, a biosimilar to Neulasta, has been a cornerstone of Coherus Biosciences' revenue, demonstrating robust growth. In fiscal year 2024, net product sales for UDENYCA surged by an impressive 62% year-over-year, reaching $206.0 million. This strong performance underscores its position as a significant cash cow for the company.\u003c\/p\u003e\n\u003cp\u003eBy the third quarter of 2024, UDENYCA held a solid 28% market share in the pegfilgrastim sector, maintaining its second-place ranking. Despite Coherus's announcement in December 2024 regarding the planned divestiture of the UDENYCA franchise, with the sale anticipated to finalize in the first or second quarter of 2025, its historical contribution as a substantial cash generator remains a key aspect of its profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUDENYCA On-Body Injector\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUDENYCA On-Body Injector, launched in February 2024, is positioned as a strong Cash Cow for Coherus Biosciences. Its rapid adoption, fueled by substantial customer demand and secured payer coverage, highlights its market strength. \u003c\/p\u003e\n\u003cp\u003eThe success is evident in the unit demand for the autoinjector, which surged by an impressive 158% in the first quarter of 2024 when compared to the preceding quarter. This growth trajectory indicates a robust and expanding market presence, solidifying its Cash Cow status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Biosimilar Portfolio (prior to divestitures)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBefore its strategic shift, Coherus Biosciences had a solid foundation with established biosimilar products like UDENYCA. These offerings were in mature markets, meaning they typically held significant market share and reliably generated cash with reduced marketing spend.  This cash flow was crucial for funding the company's later transition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Efficiency from Biosimilar Experience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCoherus Biosciences' deep bench of experience in the biosimilar market has honed its operational capabilities, creating a significant advantage for its new oncology ventures. This expertise translates into streamlined development pathways and efficient commercialization strategies.\u003c\/p\u003e\n\u003cp\u003eThe company's track record in navigating complex regulatory landscapes for biosimilars, even with divested products, demonstrates a robust and adaptable business model. This operational muscle can be directly applied to accelerating the launch and market penetration of its oncology pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eOperational Efficiency:\u003c\/strong\u003e Coherus has a proven ability to manage the entire lifecycle of biosimilar products, from development to market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Expertise:\u003c\/strong\u003e Successfully brought multiple biosimilars to market, indicating strong regulatory submission and approval capabilities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCommercialization Prowess:\u003c\/strong\u003e Established commercial infrastructure and experience in marketing and distributing complex biologic products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCost Management:\u003c\/strong\u003e Biosimilar development often necessitates stringent cost controls, which Coherus has likely mastered and can leverage in its oncology segment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Divestitures for Capital Generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCoherus Biosciences strategically divested its UDENYCA franchise, a move that generated substantial capital. The deal was valued at up to $558.4 million, with a significant portion, $483.4 million, received upfront by April 2025. This infusion of cash was crucial for strengthening the company's financial standing.\u003c\/p\u003e\n\u003cp\u003eThis divestiture was part of a broader strategy to optimize the company's portfolio and generate capital. By converting existing assets into readily available funds, Coherus aimed to achieve several key financial objectives. The primary goal was to reduce outstanding debt, thereby improving the company's balance sheet.\u003c\/p\u003e\n\u003cp\u003eFurthermore, the capital generated from these strategic divestitures, including the earlier sales of CIMERLI and YUSIMRY, was earmarked for investment in Coherus's promising oncology pipeline. This proactive approach allows the company to fund the development of innovative treatments, positioning it for future growth and market leadership.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eUDENYCA Franchise Divestiture:\u003c\/strong\u003e Up to $558.4 million in total value.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eUpfront Payment Received:\u003c\/strong\u003e $483.4 million by April 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Objectives:\u003c\/strong\u003e Debt reduction and funding of the oncology pipeline.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePortfolio Optimization:\u003c\/strong\u003e Converting existing assets into capital for future innovation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUDENYCA's $206M Revenue: A Cash Cow's Legacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUDENYCA, a biosimilar to Neulasta, served as a significant cash cow for Coherus Biosciences, demonstrating substantial revenue generation. In fiscal year 2024, net product sales for UDENYCA increased by 62% year-over-year, reaching $206.0 million, highlighting its role as a key financial contributor. Although Coherus announced plans in December 2024 to divest the UDENYCA franchise, with the sale expected to conclude in early to mid-2025, its historical performance as a strong cash generator is undeniable.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eFiscal Year 2024 Net Sales\u003c\/th\u003e\n\u003cth\u003eMarket Share (Q3 2024)\u003c\/th\u003e\n\u003cth\u003eKey Characteristic\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUDENYCA\u003c\/td\u003e\n\u003ctd\u003e$206.0 million\u003c\/td\u003e\n\u003ctd\u003e28% (Pegfilgrastim Sector)\u003c\/td\u003e\n\u003ctd\u003eEstablished Cash Cow, recently divested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eCoherus Biosciences BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Coherus Biosciences BCG Matrix preview you are viewing is the identical, fully-formatted document you will receive upon purchase. This means no watermarks, no demo content, and no hidden surprises – just the complete, analysis-ready report. You can be confident that the strategic insights and professional presentation you see now will be yours to use immediately. This ensures you're getting precisely what you need for your business planning and decision-making processes without any alteration or compromise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610984890745,"sku":"coherus-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/coherus-bcg-matrix.png?v=1754749535","url":"https:\/\/growthsharematrix.com\/products\/coherus-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}